363 related articles for article (PubMed ID: 33586766)
1. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.
Taxonera C; Olivares D; Alba C
Inflamm Bowel Dis; 2022 Jan; 28(1):32-40. PubMed ID: 33586766
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
3. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
4. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
Taxonera C; Olivares D; López-García ON; Alba C
Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
[TBL] [Abstract][Full Text] [Related]
8. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
9. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
[TBL] [Abstract][Full Text] [Related]
10. REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study.
Ma C; Panaccione R; Xiao Y; Khandelwal Y; Murthy SK; Wong ECL; Narula N; Tsai C; Peerani F; Reise-Filteau M; Bressler B; Starkey SY; Loomes D; Sedano R; Jairath V; Bessissow T;
Am J Gastroenterol; 2023 May; 118(5):861-871. PubMed ID: 36580497
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Tofacitinib for Ulcerative Colitis: Systematic Review and Meta-analysis.
Taneja V; El-Dallal M; Haq Z; Tripathi K; Systrom HK; Wang LF; Said H; Bain PA; Zhou Y; Feuerstein JD
J Clin Gastroenterol; 2022 Nov-Dec 01; 56(10):e323-e333. PubMed ID: 34516458
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S
World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.
Ledder O; Dolinger M; Dubinsky MC; Stein R; Vellanki S; Buckuk R; Fatima A; Suskind DL; Scarlett J; Röser D; Shouval DS; Meyer G; Rios ZM; Pujol-Muncunill G; Lozano A; Kolho KL; Rohani P; Hussey S; de Mejj T; Ayers T; Navas-López VM; Turner D; Tzivinikos C
Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38828483
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
Uzzan M; Bresteau C; Laharie D; Stefanescu C; Bellanger C; Carbonnel F; Serrero M; Viennot S; Nachury M; Amiot A; Altwegg R; Picon L; Nahon S; Vuitton L; Ah Soune P; Kirchgesner J; Peyrin-Biroulet L; Bouhnik Y;
Aliment Pharmacol Ther; 2021 Aug; 54(3):312-319. PubMed ID: 34151448
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study.
Molander P; Kosunen M; Eronen H; Tillonen J; Käräjämäki A; Heikkinen M; Punkkinen J; Mattila R; Toppila I; Hölsä O; Kalpala K; Henrohn D; Af Björkesten CG
Scand J Gastroenterol; 2024 Apr; 59(4):425-432. PubMed ID: 38156792
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis.
Singh A; Mahajan R; Midha V; Kaur K; Singh D; Kaur R; Garg S; Arora K; Bansal N; Sood A
Dig Dis Sci; 2024 Apr; 69(4):1389-1402. PubMed ID: 38358458
[TBL] [Abstract][Full Text] [Related]
17. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.
Adimadhyam S; Lewis JD; Simon AL; Wolfe AE; Smith S; Hou L; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett L; Haynes K; Burris J; Dorand JE; Long MD; Kappelman MD
Inflamm Bowel Dis; 2024 Apr; 30(4):554-562. PubMed ID: 37358904
[TBL] [Abstract][Full Text] [Related]
18. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
[TBL] [Abstract][Full Text] [Related]
19. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
Inflamm Bowel Dis; 2024 Mar; 30(3):395-401. PubMed ID: 37209416
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
